| Company/Division name | Takeda Pharmaceutical |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Boston |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, cell therapy, Biotech, pharmaceuticals |
| Product(s) reshored | CAR-NK, TAK-007, CAR-T therapy, cell therapy |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure |
